SUBURBAN LUNG ASSOCIATES, S.C.

Eberle Medical Building, 800 Biesterfield road, Suite 510 Elk Grove Village, IL 60007

NAME......Kuljeet Kaur Gill M.D.

Nickname: Kelly

Address: Suburban Lung Associates SC

800 Biesterfield Rd, Suite 510 Elk Grove Village IL 60007

Central DuPage Hospital 25 N Winfield Road Winfield IL 60190

Edward Hospital 801 S Washington St Naperville IL 60540

Board Certification Diplomate, American Board of Psychiatry and

Neurology, 2004 (Certificate # 52753)

Diplomate, American Board of Sleep Medicine, 2005

Diplomate, American Board of Clinical Neurophysiology, 2007

Positions and Appointments

September 2007-Present Suburban Lung Associates & Chicago

Sleep Group

October 2005 – May 2006

Cleveland Clinic Florida, Naples Associate Professor of Neurology Director of Sleep Disorders Center &

Laboratory

6101 Pine Ridge Road Naples, FL 34119

May 2006- April 2007

(In May 2006 Cleveland Clinic sold hospital and changed entities to Physicians Regional Madical Contant and Madical Contant

Medical Center and Medical Surgical

Specialists)

Department of Neurology

Director of Sleep Center & Laboratory 6101 Pine Ridge Road Naples, FL 34119

July 2004- June 2005 NIH Sponsored Research Fellow,

Division of Sleep Medicine Department of Neurology Northwestern Memorial Faculty

Foundation

July 2000- June 2003 Senior and Junior Resident

Department of Neurology

Loyola University Medical Center

Loyola University, Stritch School of Medicine

Chicago, Illinois

June 1999- June 2000 Junior Resident

Department of Internal Medicine Loyola University Medical Center

Maywood, Illinois

Education

Medical School......Saba University

College of Medicine

Netherlands-Antilles- Basic Sciences Gardner, Massachusetts- Clinical Office

Degree- MD 1995

Graduate School.......Chicago Medical School

North Chicago, Illinois

Applied Physiology Department

Degree- MS 1995

Graduate School......Northwestern University

Evanston, Illinois

Biotechnology Department- Research

College......Northwestern University

Evanston, Illinois

Communication Disorders and Sciences;

Pre-Medical Studies Degree- B.S 1993

Professional Organizations

2003-Present American Medical Association

2000-Present American Academy of Neurology

2003-present American Clinical Neurophysiology Society 2004-present American Academy of Sleep Medicine

Licensure 2003-present Medicine, State of Illinois

License Number 036-108659

Medicine, State of Florida License Number 89031

Medicine, State of Washington

License Number 45097

Medicine, State of Colorado License Number 44130

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT NATIONAL MEETINGS:

Gill, K, Park, Y. Severity of Restless Legs Syndrome and Sensory Nerve Dysfunction. Associated Professional Sleep Societies, 2005. Abstract – *Sleep* Volume 28 2005

I. PROJECTS AND RESEARCH

Principle investigator for Medical Surgical Specialists
Phase IV A randomized, double-blind placebo-controlled, parallel group clinical trial comparing placebo and pramiprexole (Miraprex) 0.25 mg administered orally to investigate the safety and efficacy in patients with idiopathic Restless Legs Syndrome for 6 weeks. Sponsor: Boehringer Ingelheim

Sleep Medicine/ Clinical Neurophysiology Fellow:

Exercise: A countermeasure for sleep loss in older adults (PI: Zee), NIH/NIA Program Project Grant, 1P01 AG 114112, "Alterations of Sleep and Circadian Timing in Aging" (E. VanCauter).

Grant Proposal: National Multiple Sclerosis Society: Abnormal Nocturnal Ventilatory Control as Sequelae of Intrathecal Baclofen Treatment

Principle Investigator: Severity of Restless Legs Syndrome and Sensory Nerve Dysfunction.

Case Series: Delayed Sleep Phase Syndrome presenting with Refractory Hypersomnia.

A randomized, double-blind placebo-controlled, parallel group clinical trial comparing fixed doses of 0.25mg, 0.50 mg, and 0.75mg pramiprexole (Miraprex) administered orally to investigate the safety and efficacy in patients with idiopathic Restless Legs Syndrome for 12 weeks. Sponsor: Boehringer Ingelheim

Evaluation of the long-term efficacy and safety of Zolpidem-MR 12.5mg compared to placebo, when both are administered over a long-term period "as needed", in patients with chronic primary insomnia. (A randomized, double-blind placebo-controlled, parallel group, multicenter, phase IIIb clinical study). Sponsor: Sanofi-Synthelabo Research, USA

A randomized, double-blind placebo-controlled study to Assess the Subjective Response to Treatment with Ramelteon (TAK – 375) in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) For Collecting Diary Data Sponsor: Takeda Global Research and Development

A Phase II, double-blind, placebo-controlled, randomized, parallel-group, multicenter study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) in Subjects with Restless Legs Syndrome (RLS) Sponsor: Kyowa Pharmaceuticals, Inc.

A multi-center, randomized, double-blind, placebo-controlled, five-arm parallel-group trial to investigate the efficacy and safety of four different transdermal doses of rotigotine in subjects with idiopathic Restless Legs Syndrome Sponsor: Schwarz Biosciences, Inc.

Neurology Residency:

Principle Investigator: Effects of NOGO-A Blockade on Dopaminergic Fiber Growth in the Adult Rat after Stroke.

Principle Investigator: Utility of Nerve and Muscle Biopsy in Diagnosis of Vasculitic Neuropathy & Myopathy.

Graduate Student:

Posttranslational mutation of 'AUUUA' sequence in rat neurons with diabetes mellitus.

Language and cognitive dysfunction in autistic children.